What is cancer research, and how is it important?
Cancer research is a vital and groundbreaking undertaking that not only increases our understanding of one of the most complex collections of diseases but also drives improvements in prevention, diagnosis, treatment, and, eventually, a search for a cure.
Known as oncology, it unites scientists, physicians, patients, and health professionals in the collective endeavor to untangle the biological mechanisms of cancer growth, spread, and development. Through the instrumentality of decades of cross-disciplinary research, we have developed more precise and more effective therapies that produce miracles for early disease detection, target-specific treatments, and prevention. The path of discovery is an interactive process by which knowledge is infused from laboratory benches to the patient’s bedside and back again. Cancer research takes place in several interrelated fields: basic research examines fundamental biological processes; translational research closes the gap between laboratory discovery and medical use; clinical research evaluates treatments within routine medicine; and population research surveys patterns and causes of cancer at the population level.
Collectively, these activities form a dynamic and ever-changing cycle, in which each step is a building block for the next to minimize the human and economic cost of cancer and offer the promise of durable cures.
What is cell viability assay, and how is it important in cancer research?
Cell viability and cytotoxicity assays are critical tools to develop novel cancer treatments, delivering crucial information on the mode of action of a potential therapy on living cells. Cell viability, the percentage of surviving living cells after treatment with a compound, is a critical measure of the efficacy and safety of a drug. Since different agents affect cellular metabolism and integrity in diverse ways, evaluating cell viability allows researchers to discern which compounds may yield the most favorable therapeutic outcomes. Complementary to this is the assessment of cytotoxicity, which tk studies the extent to which a substance induces cell damage or death, particularly through mechanisms like apoptosis (programmed cell death) or necrosis (loss of membrane integrity). Together, these measures help establish a balance between maximizing cancer cell destruction and minimizing harm to normal tissues, a crucial consideration in cancer treatment development.
A range of sophisticated assays has been developed to evaluate cell viability and cytotoxicity, from imaging-based techniques like confocal and optical (IVIS) imaging to biochemical tests that examine metabolic activity and membrane integrity. These relevant in vivo and in vitro methods are also commonly applied in toxicokinetics and cancer research to establish how chemicals, drugs, and environmental toxins affect human health. Cytotoxicity assays, for instance, are significant in high-throughput compound library screening, whereby researchers can have a tool to assess compounds where the therapeutic lead potential can be identified while simultaneously elucidating mechanisms of cell damage. With the pharmaceutical industry increasingly employing these cost-effective, non-destructive assays, reliance on animal testing has decreased, reducing drug development time. With cancer, in which unlimited cell growth is the defining characteristic, these tests are a critical part of refining treatments that selectively kill cancer cells, improving the effectiveness of treatments, and reducing toxic side effects.
What are the various types of cell viability assays used in cancer research?
In cancer research, a broad selection of cell viability assays is key to obtaining necessary information about the efficacy and safety of therapeutic compounds by evaluating the health and function of viable cells. The assays typically belong to three general classes: metabolic assays, cytotoxicity assays, and cell proliferation or cell cycle assays. Metabolic assays measure enzymatic activity in living cells by detecting the presence of metabolic byproducts through dyes or luminescence. Tetrazolium-based assays (e.g., MTT, MTS, and WST-1) register colorimetric changes by the metabolic status of the cell, whereas resazurin-based assays produce fluorescence as resazurin is reduced to resorufin in living cells. Other metabolic assays quantify mitochondrial membrane potential with dyes such as TMRE or JC-1, and esterase activity assays such as Calcein AM report enzymatic activities in the intracellular space. Lastly, ATP-based assays wherein cellular energy stores are quantified with luciferase reaction are of high speed and highly sensitive detection. Both approaches possess distinct strengths and weaknesses in terms of sensitivity, toxicity, and compatibility with live-cell imaging or high-throughput platforms, hence making the choice of assay important based on the experimental goal.
Must Read: How Assay Labs Drive Drug Development & Biomedical Research
Complementary to viability testing, cytotoxicity and proliferation assays offer deeper perspectives into drug-induced cellular outcomes. Cytotoxicity assays identify cell damage through markers such as loss of membrane integrity or enzyme leakage—commonly using LDH release, dye exclusion techniques (e.g., DRAQ7, 7-AAD), or live/dead staining kits. These assays reveal whether a reduction in viability results from acute toxicity or other cellular injuries. Concurrently, proliferation assays measure cell division rates to distinguish between growing and non-dividing or dormant cells. Assays include incorporation of nucleoside analogs (e.g., EdU or BrdU), dilution of the dye with CFSE, and immunostaining against proliferation antigens such as Ki67, PCNA, or MCM proteins. They play a critical role in oncology in probing tumor aggressiveness, monitoring responses to treatment, and developing improved therapies. Finally, by integrating multiple types of assays, investigators are able to create a three-dimensional perspective of the impact of cancer therapies on cell viability, toxicity, and proliferative potential—facilitating more focused, effective, and personalized drug development.
Conclusion:
Cell Viability Assays are a gem for cancer researchers and are used pervasively for testing drug effectiveness, compound screening, and characterization of responses to tumor cells. New luminescent assays, such as CellTiter-Glo®, are gaining favor as they are exceptionally sensitive, uncomplicated assays to execute, and also suitable for high-throughput screenings. These detect cellular ATP concentrations as indicators of cellular metabolic processes, rendering them a standard addition to basic and translational oncology research.